Shares of Regeneron Pharmaceuticals Inc. slipped 1.30% to $722.37 Friday, on what proved to be an all-around dismal trading session for the stock market,...
From a Regeneron co-founder to a medical equipment firm employee, meet 19 U.S. healthcare billionaires, per Forbes’ real-time net worth tracker:
In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Pharmaceutical Stocks to Buy According to Steven…
A generally gloomy public market hasn’t stopped biotechs with big clinical plans from raking in the cash — either through stock offerings or loans. Replimune is taking the latter route, inking a deal to borrow $200 million from Hercules Capital over the next five years in multiple tranches. For the
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time th…
Shares of Regeneron Pharmaceuticals Inc. inched 0.60% higher to $739.54 Tuesday, on what proved to be an all-around positive trading session for the stock...
Largely funded by government grants for the better part of its first decade, a UC Berkeley spinout has secured a new CEO and the funds to take its research into the clinic in early 2024. The biotech, named by one of the co-founder’s daughters and originally scrapped together with NIH
There are some odd-looking purple creatures lurking around the halls of AstraZeneca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma. The “Ast…
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors,...
The Goldman Sachs Group raised their price target on Regeneron Pharmaceuticals from $796.00 to $970.00 and gave the company a “buy” rating in a report on Monday.
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Regeneron Pharmaceuticals shares are trading higher after Goldman Sachs maintained a Buy on the stock and Benzinga
Financial Disclosure I have the following financial interests or relationships to disclose: ... | October 3, 2022
Shares of Regeneron Pharmaceuticals Inc. shed 0.43% to $688.87 Friday, on what proved to be an all-around dismal trading session for the stock market, with...
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials...
Robert Sansone, a senior at Fort Pierce Central High School in Florida, was born to invent. His creations range from springy leg extensions for sprinting to a go-kart that can reach speeds of 70 mph. But his latest project aims to solve a global problem: the unsustainability of electric car motors,…
Financial Disclosure I have the following financial interests or relationships to disclose: ... | October 1, 2022
/PRNewswire/ -- For the seventh year, Science News is spotlighting 10 early- and mid-career scientists on their way to widespread acclaim. Driven by their...
Global Diabetic Retinopathy Market Size, Share & Trends, COVID-19 Impact Analysis Report, By Type (Proliferative Diabetic Retinopathy, Diabetic Macular...
Shares of Regeneron Pharmaceuticals Inc. advanced 1.32% to $697.33 Friday, on what proved to be an all-around rough trading session for the stock market,...